Pharmacokinetic and clinical equivalence of oral and intravenous ibandronate for metastatic bone disease
Open Access
- 30 April 2004
- journal article
- Published by Elsevier in European Journal of Cancer Supplements
- Vol. 2 (5) , 9-12
- https://doi.org/10.1016/j.ejcsup.2004.01.003
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnnals of Oncology, 2003
- Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast CancerJournal of Clinical Oncology, 2002
- Should bisphosphonates be the treatment of choice for metastatic bone disease?Seminars in Oncology, 2001
- Bone metastases: Approaches to managementSeminars in Oncology, 2001
- A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.Supportive Care in Cancer, 2001
- Management of Bone MetastasesThe Oncologist, 2000
- Oral bisphosphonatesCancer, 2000
- Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone diseaseAnnals of Oncology, 1999
- Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.Journal of Clinical Oncology, 1998
- Clodronate kinetics and bioavailabilityClinical Pharmacology & Therapeutics, 1982